GlassScriptPhysician profile
Adriana Sablan
NPI 1154357358
$1,606.58
in general payments reported to CMS, 2019-2025
19 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2022: $58.96 · 2023: $255 · 2024: $540 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.95 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $261.17 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $260.42 | 2019-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $233.14 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $218.16 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.68 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $99.43 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $83.25 | 2024-2025 | |
| Pfizer INC. | $59.79 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $54.76 | 2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.20 | 2019-2025 | Jardiance |
| Sanofi Pasteur INC. | $32.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.78 | 2024 | |
| Sumitomo Pharma America, INC. | $22.43 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $21.37 | 2025 | Heplisav-B |
| Dexcom, INC. | $20.79 | 2024 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.83 | 2019 | |
| Currax Pharmaceuticals LLC | $15.51 | 2023 | Contrave, Nexletol, Nexlizet |
| Medtronic USA, INC. | $15.50 | 2019 | |
| Abbott Laboratories | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Sablan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.